The Function of SPARC as a Mediator of Fibrosis
暂无分享,去创建一个
[1] T. Wong,et al. In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon’s fibroblasts: comparisons with mitomycin C , 2012, Journal of cellular and molecular medicine.
[2] M. Colombo,et al. SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. , 2011, The American journal of pathology.
[3] O. Podhajcer,et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. , 2011, The Journal of investigative dermatology.
[4] R. Brekken,et al. SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. , 2011, American journal of physiology. Heart and circulatory physiology.
[5] J. Ampuero,et al. Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010 , 2011, PloS one.
[6] R. Brekken,et al. The regulatory function of SPARC in vascular biology , 2011, Cellular and Molecular Life Sciences.
[7] R. Brekken,et al. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-b1 activity , 2011 .
[8] R. Brekken,et al. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity , 2011, The Journal of cell biology.
[9] S. Friedman,et al. SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[10] C. Rossa,et al. LPS Induces Greater Bone and PDL Loss in SPARC-null Mice , 2011, Journal of dental research.
[11] H. Chapman,et al. Epithelial-mesenchymal interactions in pulmonary fibrosis. , 2011, Annual review of physiology.
[12] M. Le Hir,et al. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? , 2011, The Journal of clinical investigation.
[13] A. Jünemann,et al. SPARC is expressed in scars of the Tenon’s capsule and mediates scarring properties of human Tenon’s fibroblasts in vitro , 2011, Molecular vision.
[14] A. Bradshaw,et al. SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[15] F. Arnett,et al. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA , 2010, Arthritis research & therapy.
[16] S. Heymans,et al. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). , 2010, Journal of molecular and cellular cardiology.
[17] T. Aung,et al. SPARC Deficiency Results in Improved Surgical Survival in a Novel Mouse Model of Glaucoma Filtration Surgery , 2010, PloS one.
[18] M. Zile,et al. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. , 2010, American journal of physiology. Heart and circulatory physiology.
[19] S. Cohn,et al. Modulation of matrix remodeling by SPARC in neoplastic progression. , 2010, Seminars in cell & developmental biology.
[20] G. Rosen,et al. SPARC Suppresses Apoptosis of Idiopathic Pulmonary Fibrosis Fibroblasts through Constitutive Activation of β-Catenin* , 2010, The Journal of Biological Chemistry.
[21] E. Hohenester,et al. Crystallographic Insight into Collagen Recognition by Discoidin Domain Receptor 2 , 2009, Structure.
[22] R. Durvasula,et al. SPARC accelerates disease progression in experimental crescentic glomerulonephritis. , 2009, The American journal of pathology.
[23] J. Lacy,et al. Pressure Overload–Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function: Role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Post–Synthetic Procollagen Processing , 2009, Circulation.
[24] Takako Sasaki,et al. Structural basis of sequence-specific collagen recognition by SPARC , 2008, Proceedings of the National Academy of Sciences.
[25] O. Podhajcer,et al. Adenovirus‐mediated inhibition of SPARC attenuates liver fibrosis in rats , 2008, The journal of gene medicine.
[26] E. Sage,et al. The Copper Binding Domain of SPARC Mediates Cell Survival in Vitro via Interaction with Integrin β1 and Activation of Integrin-linked Kinase* , 2008, Journal of Biological Chemistry.
[27] I. Lawrance,et al. Indomethacin and Retinoic Acid Modify Mouse Intestinal Inflammation and Fibrosis: A Role for SPARC , 2008, Digestive Diseases and Sciences.
[28] P. Bornstein,et al. SPARC Regulates Processing of Procollagen I and Collagen Fibrillogenesis in Dermal Fibroblasts* , 2007, Journal of Biological Chemistry.
[29] F. Arnett,et al. Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. , 2006, Arthritis and rheumatism.
[30] William P Schiemann,et al. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.
[31] J. Davidson,et al. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. , 2003, The Journal of investigative dermatology.
[32] E. Sage,et al. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] C. Alpers,et al. Amelioration of diabetic nephropathy in SPARC-null mice. , 2003, Journal of the American Society of Nephrology : JASN.
[34] D. Arking,et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.
[35] C. Alpers,et al. Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. , 2002, Kidney international.
[36] R. Macko,et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.
[37] P. Bornstein,et al. Matricellular proteins: extracellular modulators of cell function. , 2002, Current opinion in cell biology.
[38] S. Seki,et al. Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis , 2002, Virchows Archiv.
[39] R. Savani,et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[40] K. Dohi,et al. Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury , 2000, Diabetologia.
[41] M. Amling,et al. Osteopenia and decreased bone formation in osteonectin-deficient mice , 2000, The Journal of clinical investigation.
[42] W. Couser,et al. SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.
[43] E. Sage,et al. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. , 1999, American journal of physiology. Lung cellular and molecular physiology.
[44] E. Sage,et al. SPARC deficiency leads to early-onset cataractogenesis. , 1998, Investigative ophthalmology & visual science.
[45] R. Timpl,et al. Crystal structure and mapping by site‐directed mutagenesis of the collagen‐binding epitope of an activated form of BM‐40/SPARC/osteonectin , 1998, The EMBO journal.
[46] A. Hendrickson,et al. SPARC Is Expressed by Ganglion Cells and Astrocytes in Bovine Retina , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[47] K. Okubo,et al. Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts. , 1997, The American journal of pathology.
[48] M. Cooper,et al. Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system. , 1997, Journal of the American Society of Nephrology : JASN.
[49] M. Reed,et al. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. , 1996, Kidney international.
[50] M. Reed,et al. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. , 1996, The American journal of pathology.
[51] R. Mason,et al. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. , 1995, The American journal of pathology.
[52] L. Malaval,et al. SPARC, an extracellular matrix glycoprotein containing the follistatin module, is expressed by astrocytes in synaptic enriched regions of the adult brain , 1995, Brain Research.
[53] M. Eghbali,et al. Expression of SPARC in normal and fibrotic livers , 1995, Hepatology.
[54] G. Webersinke,et al. Comparison of gene expression of extracellular matrix molecules in brain microvascular endothelial cells and astrocytes. , 1992, Biochemical and biophysical research communications.
[55] J. Wrana,et al. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. , 1991, European journal of biochemistry.
[56] E. Vuorio,et al. Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. , 1991, The Journal of rheumatology.
[57] E. A. Everitt,et al. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix , 1989, The Journal of cell biology.
[58] S. Funk,et al. SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. , 1989, Journal of molecular and cellular cardiology.
[59] P. Holland,et al. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization , 1987, The Journal of cell biology.
[60] A. Schulz,et al. Osteonectin — a differentiation marker of bone cells , 1987, Cell and Tissue Research.
[61] G. Riemekasten,et al. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. , 2011, VASA. Zeitschrift fur Gefasskrankheiten.
[62] G. Riemekasten,et al. Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. , 2011, VASA. Zeitschrift fur Gefasskrankheiten.
[63] N. Said,et al. Cardiovascular , Pulmonary and Renal Pathology Secreted Protein Acidic and Rich in Cysteine Deficiency Ameliorates Renal Inflammation and Fibrosis in Angiotensin Hypertension , 2007 .
[64] D. Milewicz,et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. , 2005, Arthritis and rheumatism.
[65] D. Milewicz,et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor β1 in cultured normal human fibroblasts , 2005 .
[66] D. Arking,et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.
[67] R. Ross,et al. Inhibition of PDGF‐stimulated and matrix‐mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin‐dependent kinase inhibitors , 2002, Journal of cellular biochemistry.
[68] A B West,et al. Myofibroblasts: paracrine cells important in health and disease. , 2000, Transactions of the American Clinical and Climatological Association.
[69] D. Powell,et al. Powell, D. W. et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1-C9 , 1999 .